CD274 and neoplasm: The recent revolution in immunotherapy has been driven by identifying immune checkpoints, whereby either tumor cells or antigen-presenting dendritic cells can present ligands such as PD-L1 or B7 to checkpoint receptors on T cells, the PD1 receptor, or CTLA-4.